Second Vertex drug caught in CF standoff

NICE's suspension of its review of Symkevi tezacaftor/ivacaftor on Thursday marks the latest delay of access in England and Wales to cystic fibrosis drugs from Vertex Pharmaceuticals Inc. (NASDAQ:VRTX).

NICE suspended its review after the company did not provide an evidence submission, according to the committee's website. It also

Read the full 492 word article

User Sign In